STOCK TITAN

Zai Lab Announces Participation in November Investor Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announces participation in investor conferences in November 2023.
Positive
  • Zai Lab Limited (ZLAB) will participate in the Jefferies London Healthcare Conference on November 15th and the Evercore ISI HealthCONx Conference on November 29th. These conferences provide opportunities for networking and exposure to potential investors.
Negative
  • None.

SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023:

Jefferies London Healthcare Conference
Fireside Chat: Wednesday, November 15th at 1:00 p.m. GMT
Location: London

6th Annual Evercore ISI HealthCONx Conference
Fireside Chat: Wednesday, November 29th at 1:45 p.m. EST
Location: Miami

A live webcast of the presentations will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replays will be available for up to 90 days following the completion of each event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: 
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media: 
Shaun Maccoun / Xiaoyu Chen
+1 (415) 317-7255 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited


FAQ

What conferences will Zai Lab Limited participate in November 2023?

Zai Lab Limited will participate in the Jefferies London Healthcare Conference and the Evercore ISI HealthCONx Conference in November 2023.

Where can I access the webcast of the presentations?

The live webcast of the presentations will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-presentations.

How long will the archived replays be available?

The archived replays will be available for up to 90 days following the completion of each event.

Zai Lab Limited American Depositary Shares

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Stock Data

1.58B
887.81M
1.83%
44.84%
3.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SHANGHAI

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve